Skip to content

Clinical trials

Observational Renal Insufficiency, Chronic trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Renal Insufficiency, Chronic Phase: Observational Country / region: Italy Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20062
20092
20102
20111
20131
20142
20161
20193
20204
20212
20222
20232
20244
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed19
Recruiting6
Unknown status4
Active, not recruiting1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca4
Mario Negri Institute for Pharmacological Research3
Amgen2
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS2
Heidelberg University2
Istituto Nazionale di Ricovero e Cura per Anziani2
Novo Nordisk A/S2
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria1
Azienda USL Toscana Nord Ovest1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Renal Insufficiency, Chronic31
Heart Failure4
Kidney Failure, Chronic4
Anemia3
Diabetes Mellitus, Type 22
Hyperkalemia2
Hypertension2
Polycystic Kidney, Autosomal Dominant2
Pulmonary Disease, Chronic Obstructive2
Vascular Diseases2

Trials

Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.